Business
Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®
MONTPELLIER, France, September 22, 2025--Regulatory News: Medincell (Paris:MEDCL):
About this update from Teva Pharmaceutical Industries Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/c030ee0ba01d25be5e0128d05cb9392f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jRKXjNpOvXILl_0vdRl3Qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c030ee0ba01d25be5e0128d05cb9392f","width":960,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/lR73swOP_sDh0pbhAleCaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEwNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c030ee0ba01d25be5e0128d05cb9392f","width":640,"height":107},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/qao2aiLslEQC8mDz3z8fnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c030ee0ba01d25be5e0128d05cb9392f","width":1200,"height":200}},"lazy":false},{"type":"text","content":"UZEDY® was associated with a 2.89-day shorter length of hospital stay compared with Invega Sustenna® (paliperidone palmitate)","length":125,"tagName":"p"},{"type":"text","content":"This translates to estimated direct cost savings of $3200 per hospitalization","length":77,"tagName":"p"},{"type":"text","content":"More Healthcare Practitioners (HCPs) favored UZEDY® over Invega Sustenna® for ease of administration, initiation, dosing characteristics and subcutaneous injection features","length":172,"tagName":"p"},{"type":"text","content":"The new data were showcased in one of ten schizophrenia-related posters presented by Medincell’s partner, Teva, at the 2025 Psych Congress, held from September 17 to 21 in San Diego, California","length":193,"tagName":"p"},{"type":"text","content":"MONTPELLIER, France, September 22, 2025--(BUSINESS WIRE)--Regulatory News:","length":74,"tagName":"p"},{"type":"text","content":"Medincell (Paris:MEDCL):","length":24,"tagName":"p"},{"type":"text","content":"UZEDY® (1-month and 2-month subcutaneous risperidone for treatment of schizophrenia), is the first product based on Medincell's long-acting injection technology that reached commercial stage. UZEDY was approved in the U.S. for the treatment of schizophrenia in adults in 2023.","length":280,"tagName":"p"},{"type":"text","content":"Medincell’s partner Teva led the clinical development and r...